• The Daily Trade
  • Posts
  • Market Moves: Navigating Recovery Amidst Trump's Impact and Key Earnings Ahead

Market Moves: Navigating Recovery Amidst Trump's Impact and Key Earnings Ahead

The Daily Trade delivers sharp, daily insights on the US stock market.

Start your day with a quick look at top market news, then dive into our technical analysis of over 10,000 stocks to uncover overbought and oversold opportunities.

Stay informed, spot trends, and trade with confidence— no fluff, just actionable intel.



How major US stock indexes fared Monday (1 minute read)
Most U.S. stocks experienced a slight recovery on Monday, with the S&P 500 rising 0.4% and the Nasdaq gaining 0.6%, while the Dow slipped 0.1%. This uptick followed a significant decline the previous week, aided by easing Treasury yields and positive news from CVS Health, as major companies prepare to report quarterly results, including Nvidia on Wednesday.


Trump Euphoria Peaks: Markets High, Signs of Reversal Loom (23 minute read)
The article discusses recent market fluctuations following Trump's election, highlighting a brief surge in stock prices that quickly reversed, raising concerns about overvaluation and potential inflation due to proposed policies. It notes that while inflation indicators have risen, long-term prospects for precious metals remain strong despite short-term pressures from a stronger dollar and rising interest rates, suggesting a cautious outlook for investors amid signs of a potentially overvalued market.


Survival Stakes: Super Micro's Critical Exchange Lifeline (2 minute read)
Super Micro Computer's stock surged nearly 20% to an intraday high of $22.70, making it the top performer in the S&P 500, as investors await the company's compliance plan submission to the Nasdaq to avoid delisting. The urgency follows delays in filing its annual 10-K and quarterly 10-Q reports, with a compliance deadline set for November 16, which could stabilize investor sentiment and impact the broader tech ecosystem if successfully navigated.


Market Volatility: Are We Due for a Bounce? Key Stocks to Watch Today (2 minute read)
The stock market faced a volatile week marked by significant pullbacks in major indices, particularly with a notable 2.5% decline on Friday that raised concerns about deeper issues. Key support levels for potential rebounds are being approached, and stocks like NVIDIA, Tesla, and Coinbase are highlighted as focal points for trading opportunities amid ongoing earnings reports and market developments.




Technical Analysis Results

Overvalued
BE
Bloom Energy Corporation
Volume: 38.4M shares | Price: $22.81

30 Day Performance
30-Day Price History

Technical Indicator Score: 100% Sell
Out of the 8 technical indicators that were used to analyze this stock, 8 indicated sell signals.
RSI
Sell
MFI
Sell
WillR
Sell
AO
Sell
CCI
Sell
BBANDS
Sell
ULTOSC
Sell
STOCH
Sell

Recent Mentions of BE

Bloom Energy Stock Sees RS Rating Lift Off To 97 Amid AEP Deal
Bloom Energy shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.

Trending tickers: Nvidia, Super Micro, Palantir, Reliance Industries and Boohoo
The latest investor updates on stocks that are trending on Monday.




Undervalued
REGN
Regeneron Pharmaceuticals Inc
Volume: 837.2K shares | Price: $762.00

30 Day Performance
30-Day Price History

Technical Indicator Score: 88% Buy
Out of the 8 technical indicators that were used to analyze this stock, 7 indicated buy signals, 1 indicated a neutral signal.
RSI
Buy
MFI
Buy
WillR
Buy
AO
Buy
CCI
Buy
BBANDS
Hold
ULTOSC
Buy
STOCH
Buy

Recent Mentions of REGN

FDA Accepts SNY and REGN's Dupixent Re-Submitted sBLA for Urticaria
The FDA is set to give its decision on SNY and REGN's sBLA for Dupixent for chronic spontaneous urticaria on April 18, 2025.

FDA reviews Sanofi and Regeneron’s Dupixent label expansion for urticaria
The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.




Undervalued
BIIB
Biogen Inc. Common Stock
Volume: 1.5M shares | Price: $157.94

30 Day Performance
30-Day Price History

Technical Indicator Score: 88% Buy
Out of the 8 technical indicators that were used to analyze this stock, 7 indicated buy signals, 1 indicated a neutral signal.
RSI
Buy
MFI
Hold
WillR
Buy
AO
Buy
CCI
Buy
BBANDS
Buy
ULTOSC
Buy
STOCH
Buy

Recent Mentions of BIIB

Biogen's Outlook Dims As Analyst Projects Flat Revenue Until 2026
Needham downgraded Biogen Inc (NASDAQ:BIIB), citing limited catalysts for the company over the next year. Alzheimer’s drug Leqembi’s (lecanemab) sales growth is expected to stay gradual without a sharp increase in the near future. The analyst remarked that the physician feedback and expert opinions indicate this slow pace will continue. Leqembi’s third-quarter global in-market sales were approximately $67 million, including U.S. in-market sales of approximately $39 million. Although investors ar

Needham downgrades Biogen on slow growth of Alzheimer's drug
Investing.com - Needham downgraded Biogen Inc (NASDAQ:BIIB) on Monday, citing slower-than-expected growth for its Alzheimer's drug, Leqembi, and a lack of major catalysts over the next 12 months.




Undervalued
ICLR
Icon Plc
Volume: 1.9M shares | Price: $187.22

30 Day Performance
30-Day Price History

Technical Indicator Score: 88% Buy
Out of the 8 technical indicators that were used to analyze this stock, 7 indicated buy signals, 1 indicated a neutral signal.
RSI
Buy
MFI
Buy
WillR
Buy
AO
Buy
CCI
Buy
BBANDS
Hold
ULTOSC
Buy
STOCH
Buy

Recent Mentions of ICLR

ICON Public Limited Company (ICLR): Among 12 High Growth Large Cap Stocks to Buy Now
We recently published a list of 12 High Growth Large Cap Stocks to Buy Now. In this article, we are going to take a look at where ICON Public Limited Company (NASDAQ:ICLR) stands against other high growth large cap stocks. BlackRock highlighted that its portfolio managers are broadly optimistic about US equities. Its portfolio managers opine […]

Should You Think About Buying ICON Public Limited Company (NASDAQ:ICLR) Now?
ICON Public Limited Company ( NASDAQ:ICLR ) saw significant share price movement during recent months on the NASDAQGS...




Undervalued
LINE
Lineage, Inc. Common Stock
Volume: 842.4K shares | Price: $63.61

30 Day Performance
30-Day Price History

Technical Indicator Score: 88% Buy
Out of the 8 technical indicators that were used to analyze this stock, 7 indicated buy signals, 1 indicated a neutral signal.
RSI
Buy
MFI
Buy
WillR
Buy
AO
Buy
CCI
Buy
BBANDS
Hold
ULTOSC
Buy
STOCH
Buy

Recent Mentions of LINE

Decoding Lineage Inc (LINE): A Strategic SWOT Insight
Unraveling the Financial Fabric and Strategic Directions of Lineage Inc

Lineage, Inc. Reports Third-Quarter 2024 Financial Results
NOVI, Mich., November 06, 2024--Lineage, Inc. (NASDAQ: LINE) (the "Company"), the world’s largest global temperature-controlled warehouse REIT, today announced its financial results for the third quarter of 2024.




Undervalued
CAG
Conagra Brands, Inc.
Volume: 5.7M shares | Price: $26.61

30 Day Performance
30-Day Price History

Technical Indicator Score: 88% Buy
Out of the 8 technical indicators that were used to analyze this stock, 7 indicated buy signals, 1 indicated a neutral signal.
RSI
Buy
MFI
Buy
WillR
Buy
AO
Buy
CCI
Buy
BBANDS
Buy
ULTOSC
Hold
STOCH
Buy

Recent Mentions of CAG

Conagra Brands Named to Military Times' 2024 Best for Vets: Employers List
Conagra Brands, Inc. (NYSE: CAG) today announced that it has been recognized on the 2024 Best for Vets: Employers list by Military Times. This recognition comes as the company continues to demonstrate its dedication to supporting veterans and active-duty service members, as well as their families, through strategic partnerships and internal initiatives.

Conagra Brands, Inc. (NYSE:CAG) down to US$13b market cap, but institutional owners may not be as affected after a year of 3.5% returns
Key Insights Given the large stake in the stock by institutions, Conagra Brands' stock price might be vulnerable to...




We want to hear from YOU!

Technical indicator analysis feedback request

Your feedback is important to us. We’re always looking for ways to improve and would love to hear your thoughts on how we can make this newsletter even better for you. Whether you have suggestions, ideas, or just want to share what you enjoy most, we’re all ears.

Simply reply to this email with your thoughts. Every comment helps us serve you better.

Thank you for being a valued reader.

How would you rate today's newsletter?

If there's anything I can do better, please let me know so I can make improvements!

Login or Subscribe to participate in polls.

Technical Indicator Information

Relative Strength Index (RSI) | Period: 14 days | Overvalued threshold: 70 | Undervalued threshold: 30

Money Flow Index (MFI) | Period: 14 days | Overvalued threshold: 80 | Undervalued threshold: 20

Williams Percent Range (WillR) | Period: 14 days | Overvalued threshold: -20 | Undervalued threshold: -80

Aroon Oscillator (AO) | Period: 14 days | Overvalued threshold: 75 | Undervalued threshold: -75

Moving Average Convergence/Divergence (MACD) | Period: 26/12/9 days | Overvalued threshold: MACD crosses below MACD Signal | Undervalued threshold: MACD crosses above MACD Signal

Stochastic Oscillator (STOCH) | Period: 14/3/3 days | Overvalued threshold: %K crosses below %D above 80 | Undervalued threshold: %K crosses above %D below 20

Commodity Channel Index (CCI) | Period: 20 days | Overvalued threshold: 100 | Undervalued threshold: -100

Bollinger Bands (BBANDS) | Period: 20 days | Overvalued threshold: price >= upper band | Undervalued threshold: price <= lower band

Parabolic Stop and Reverse (SAR) | Period: variable 50 - 100 days | Overvalued threshold: SAR crosses above price | Undervalued threshold: SAR crosses below price

Triple Exponential Average (TRIX) | Period: 15 days | Overvalued threshold: TRIX crosses below 0 | Undervalued threshold: TRIX crosses above 0

Ultimate Oscillator (ULTOSC) | Period: 28/14/7 days | Overvalued threshold: 70 | Undervalued threshold: 30

Directional Movement Index (DMI) | Period: 14 days | Overvalued threshold: PlusDI crosses below MinusDI | Undervalued threshold: PlusDI crosses above MinusDI

Average Directional Index (ADX) | Period: variable 14 days | Requirement: >= 25

Analysis is only performed on securities with market caps in excess of $100 million and with daily trade volume in excess of $50 million.

Disclaimers

The information in our newsletter is not intended to constitute investment advice and is not designed to meet your personal financial situation. It is provided for information purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor or a group of investors. It should not be assumed that any investments in securities, companies, sectors or markets identified and described will be profitable. We strongly advise you to discuss your investment options with your financial advisor prior to making any investments, including whether any investment is suitable for your specific needs.

Although we obtain information contained in our newsletter from sources we believe to be reliable, we cannot guarantee its accuracy. The analysis provided in this newsletter is based on the prior trading day’s closing prices and may not reflect after-hours trading, earnings announcements, or other significant market events that occur outside regular trading hours. As such, any data or commentary may not fully capture the latest market movements or emerging factors. For the most current and comprehensive view, please consider additional sources or consult with a qualified financial professional.

The information provided in our newsletter is private, privileged, and confidential information, licensed for your sole individual use as a subscriber. We reserve all rights to the content of this newsletter. Forwarding, copying, disseminating, or distributing this newsletter in whole or in part, including substantial quotation of any portion the publication or any release of specific investment recommendations, is strictly prohibited.